Log in

Nuformix Share Forecast, Price & News

GBX 3.65
-0.05 (-1.35 %)
(As of 09/23/2020 12:00 AM ET)
Today's Range
Now: GBX 3.65
50-Day Range
MA: GBX 3.94
52-Week Range
Now: GBX 3.65
Volume1.17 million shs
Average Volume3.69 million shs
Market Capitalization£17.89 million
P/E RatioN/A
Dividend YieldN/A
Nuformix plc develops pharmaceutical products using its cocrystal technology in the United Kingdom. Its lead programs include NXP001, which is used for oncology supportive care; and NXP002 for use in the treatment of fibrosis. The company is also developing NXP003, which is under the pre-clinical stage for the treatment of anti-inflammatory diseases. Nuformix plc was founded in 2008 and is headquartered in Cambridge, the United Kingdom.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.50 out of 5 stars

Industry, Sector and Symbol

Industry Biotechnology
Phone44 1223 423 667



Sales & Book Value

Annual Sales£535,000.00
Cash FlowGBX 0.09 per share
Book ValueGBX 1 per share



Market Cap£17.89 million
Next Earnings DateN/A
GBX 3.65
-0.05 (-1.35 %)
(As of 09/23/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive NFX News and Ratings via Email

Sign-up to receive the latest news and ratings for NFX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Nuformix (LON:NFX) Frequently Asked Questions

How has Nuformix's stock been impacted by COVID-19 (Coronavirus)?

Nuformix's stock was trading at GBX 5.50 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, NFX shares have decreased by 33.6% and is now trading at GBX 3.65.
View which stocks have been most impacted by COVID-19

How were Nuformix's earnings last quarter?

Nuformix PLC (LON:NFX) announced its quarterly earnings data on Wednesday, July, 22nd. The company reported ($0.16) EPS for the quarter.
View Nuformix's earnings history

Who are some of Nuformix's key competitors?

What other stocks do shareholders of Nuformix own?

Who are Nuformix's key executives?

Nuformix's management team includes the following people:
  • Dr. Daniel John Gooding, CEO & Director (Age 45)
  • Dr. Joanne M. Holland, Chief Scientific Officer & Director (Age 44)

What is Nuformix's stock symbol?

Nuformix trades on the London Stock Exchange (LON) under the ticker symbol "NFX."

How do I buy shares of Nuformix?

Shares of NFX and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What is Nuformix's stock price today?

One share of NFX stock can currently be purchased for approximately GBX 3.65.

How big of a company is Nuformix?

Nuformix has a market capitalization of £17.89 million and generates £535,000.00 in revenue each year. Nuformix employs 3 workers across the globe.

What is Nuformix's official website?

The official website for Nuformix is www.levrett.com.

How can I contact Nuformix?

Nuformix's mailing address is Ste 31 Second Fl, 107 Cheapside, LONDON, EC2V 6DN, United Kingdom. The company can be reached via phone at 44 1223 423 667.

This page was last updated on 9/24/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.